Faes Farma, S.A.
FAE.MCDrugs in Pipeline
8
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Bilastine Ophthalmic Solution 0.6%
Allergic Conjunctivitis
Desloratadine
Seasonal Allergic Rhinitis
Cetirizine
Seasonal Allergic Rhinitis
Bilastine
Allergic Conjunctivitis
Calcifediol 75mcg
Vitamin D Deficiency
Levocetirizine
Urticaria
Bilastine 0.2%
Allergic Conjunctivitis
Fexofenadine
Seasonal Allergic Rhinitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bilastine Ophthalmic Solution 0.6% | Phase 3 | Allergic Conjunctivitis | - | - |
Desloratadine | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Cetirizine | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Bilastine | Phase 3 | Allergic Conjunctivitis | - | - |
Calcifediol 75mcg | Phase 3 | Vitamin D Deficiency | - | - |
Levocetirizine | Phase 3 | Urticaria | - | - |
Bilastine 0.2% | Phase 2 | Allergic Conjunctivitis | - | - |
Fexofenadine | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Frequently asked questions
What is in Faes Farma, S.A.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Faes Farma, S.A.'s (FAE.MC) pipeline across Phase 3, Phase 2. Its lead program is Bilastine Ophthalmic Solution 0.6% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Faes Farma, S.A.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Faes Farma, S.A. (FAE.MC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FAE.MC biotech catalysts?→
Add FAE.MC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Faes Farma, S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.